Locust Walk Insights
SUBSCRIBE TO OUR INSIGHTS
LOCUST WALK INSIGHTS
2024 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2024 Q1 report applies the latest data to analyze current activities in the life sciences deal landscape.
Overview of AI in Biotech
Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline.
2023 Year-In-Review Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Year-In-Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
2023 Q3 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
2023 Q2 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Deal Makers of Japan, Volume 3
The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry. We are pleased to present the third volume of the Deal Makers of Japan - Exclusive Interviews with Japan’s best dealmakers,...
2023 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Frist Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
RNA Therapeutics Landscape Overview
Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition, Protein Expression, RNA-Targeting Small Molecules, RNA Editing, and RNA-Mediated Protein and Transcriptome Regulation.
2022 Year In Review Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Year In Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
2022 Q3 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
2022 Q2 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
2022 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 First Quarter Report applies the latest data to analyze current activities in the life sciences deal...
Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment...
2021 Year End Report
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.